Market Overview

Auxilium Pharmaceuticals Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the first cohort of patients has been dosed in its phase Ib trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of edematous fibrosclerotic panniculopathy, commonly known as cellulite. Cellulite has been reported to occur in 85-98% of post-pubertal females and rarely in men. The condition is prevalent in women of all races. (1,3)

Posted-In: News FDA

 

Related Articles (AUXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters